Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND trial of DIAG723 in adults with hereditary hemorrhagic telangiectasia
2026-526271-29-00Phase 2Authorised
- Sponsor
- Diagonal Therapeutics
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of DIAG723 in hereditary hemorrhagic telangiectasia (HHT) (3 arms), sponsored by Diagonal Therapeutics. Primary endpoints: Treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities and Change from baseline in safety assessments. Planned start Sep 2026; status: authorised.
02
Drugs
DIAG723
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2026-526271-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526271-29-00.